UnknownNot Applicable

Inflammatory Biomarkers in Seizure

90 participantsStarted 2022-10

Plain-language summary

1. Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure. 2. Possible role to predict the prognosis of patients with epileptic seizure

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: patients diagnosed as epileptic seizure are aged \>12 years patients diagnosed as psychogenic non-epileptic seizure are aged \>12 years Normal healthy control for comparison. Heathy control are aged \>12 years with no history of lifetime seizures or suspected seizures or febrile seizure and no treatment with an antiepileptic drug (AED) prior to blood draw Exclusion Criteria: * Neurological criteria: Other CNS disorders including Parkinson's disease, amyotrophic lateral sclerosis ,cerebrovascular stroke, Psychiatric disorders {major depression disorder , generalized anxiety, mania and other psychiatric diseases). Others: Tumors and cardiovascular

What they're measuring

Detection of the level of inflammatory biomarkers in epileptic seizure and psychogenic non-epileptic seizure

Timeframe: 2 years

Trial details

NCT IDNCT05556109

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10

View on ClinicalTrials.gov More Biomarkers in Seizures trials